MISSION® shRNA Human Gene Family Set
Transduction Particles

Catalog Numbers: SH0131, SH0231, SH0431, SH0531, SH0731, SH0831, SH1031, SH1131, SH1331, SH1831, SH1931, SH2131, SH2231, SH231, SH2431, SH2531, SH2631, SH2731, SH2831, SH2931, and SH3031

Storage Temperature –70 °C

TECHNICAL BULLETIN

Product Description
Small interfering RNAs (siRNAs) generated from short hairpin RNAs (shRNAs) are a powerful way to mediate gene specific RNA interference (RNAi) for extended periods of time in mammalian cells. The MISSION® product line is a viral-vector-based RNAi library against annotated mouse and human genes. MISSION shRNAs are expressed intracellularly after transduction with amphotropic lentivirus particles, allowing screening in a wide range of mammalian cell lines. In these cell lines, MISSION shRNA clones permit rapid, cost efficient loss-of-function and genetic interaction screens. We have collected a list of reviews that highlight the importance of each gene family set.

The MISSION shRNA Transduction Particles Set allows for high throughput loss-of-function and genetic interaction screens. The set consists of VSV-G pseudotyped lentiviral particles. Each MISSION shRNA clone is constructed within the lentivirus plasmid vector pLKO.1-Puro. Each gene target set consists of 3 or more constructs that have been designed against each target gene using a proprietary algorithm. Therefore, a range of knockdown efficiencies, with at least one construct from each gene set being >70%, can be expected when using these clones. This allows one to examine the effect of loss of gene function over a large series of gene knockdown efficiencies. Each shRNA construct has been cloned and sequence verified to ensure a match to the target gene.

In addition, the lentiviral transduction particles are pseudotyped with an envelope G glycoprotein from Vesicular Stomatitis Virus (VSV-G), allowing transduction of a wide variety of mammalian cells. Unlike murine-based MMLV or MSCV retroviral systems, lentiviral-based particles permit efficient infection and integration of the specific shRNA construct into differentiated and non-dividing cells, such as neurons and dendritic cells, overcoming low transfection and integration difficulties when using these cell lines.

Please see the Cell Type Table for those cell types that have been successfully infected by pLKO.1-puro based shRNA constructs.

The lentiviral transduction particles are titered via a p24 antigen ELISA assay, and pg/ml of p24 are then converted to transducing units per ml using a conversion factor. The conversion can be viewed at: www.tronolab.com.

Components/Reagents
Each individual construct is provided as 4 × 50 μL of frozen stock containing 10^6 lentiviral transducing particles per ml in Dulbecco’s Modified Eagle’s Medium with 10% heat-inactivated fetal bovine serum (FBS) and penicillin-streptomycin. 10% of the clones in a set are titered via an ELISA p24 assay for quality control. Fully titered sets are available on a custom basis; contact RNAi@sial.com for more information.

Lentivirus sets are packaged into a 96-well plate and labeled with 2-D barcodes for simple plate identification. A CD contains detailed clone position, 2-D barcode reference, RefSeq, locus link, gene description, gene symbol, clone ID, and hairpin sequence.
The hairpin sequence and other unique clone information may be obtained by searching the MISSION search database at: www.sigma.com/yfg using RefSeq accession numbers (e.g. NM_027088), unique clone identification numbers (e.g. NM_027088.1-989s1c1), or TRC numbers (e.g. TRCN0000030720).

Materials Suggested but Not Provided
- Hexadimethrine bromide, Catalog Number H9268
- Puromycin Ready Made Solution (10 mg/ml in H2O), Catalog Number P9620
- Minimum Essential Medium containing 10% fetal calf serum or growth medium optimized for the specific cell line
- 96-well cell culture treated plates
- Mammalian cells to be transduced
- Primers, probes, and PCR mix for qRT-PCR
- Cell-based, enzymatic, or array based assay for phenotypic assay

Precautions and Disclaimer
These products are for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Though the lentiviral transduction particles produced are replication incompetent, it is highly recommended that they be treated as Risk Group Level 2 (RGL-2) organisms. Follow all published RGL-2 guidelines for handling and waste decontamination. Also, use extra caution when using lentiviral transduction particles that express shRNA targeting genes involved in cell cycle control.

Storage/Stability
All components are guaranteed to be stable for at least six months after receipt when stored at –70 °C. Avoid repeated freeze/thaw cycles, as this will severely reduce transduction efficiency.

Preparation Instructions
1. Prepare mammalian cell cultures so that they are growing exponentially and are no more than 70–80% confluent before transduction.
2. Prepare a stock solution of hexadimethrine bromide (the chemical equivalent of Polybrene) at 2 mg/mL in water.

Procedure
The following protocol has been developed for high-content screening in 96-well plates with stable selection through puromycin.

Day 1.
- a. Add 1.6 x 10^4 cells in fresh medium to the number of wells needed for each construct in a 96-well plate. Duplicate or triplicate wells for each lentiviral construct and control should be used.
- b. Incubate 18–20 hours at 37 °C in a humidified incubator in an atmosphere of 5–7% CO2.

Note: The growth rates of cells vary greatly. Adjust the number of cells plated to accommodate a confluency of 70% upon transduction. Also account for the length of time the cells will be growing before downstream analysis when determining the plating density.

Day 2.
- a. Remove medium from wells. To each well add 110 μL medium and hexadimethrine bromide to a final concentration of 8 μg/mL. Gently swirl the plate to mix.
- b. Add 2–15 μL of lentiviral particles to appropriate wells. Gently swirl the plate to mix. Incubate 18–20 hours at 37 °C in a humidified incubator in an atmosphere of 5–7% CO2. Cells may be incubated for as little as 4 hours before changing the medium containing lentiviral particles. Overnight incubation may be avoided when toxicity of the lentiviral particles are a concern.

Note: Hexadimethrine bromide enhances transduction of most cell types. Some cells, like primary neurons, are sensitive to hexadimethrine bromide. Do not add hexadimethrine bromide to these types of cells. If working with a cell type for the first time, a hexadimethrine control only well should be used to determine cell sensitivity.

b. Add 2–15 μL of lentiviral particles to appropriate wells. Gently swirl the plate to mix. Incubate 18–20 hours at 37 °C in a humidified incubator in an atmosphere of 5–7% CO2. Cells may be incubated for as little as 4 hours before changing the medium containing lentiviral particles. Overnight incubation may be avoided when toxicity of the lentiviral particles are a concern.

Note: When transducing a lentiviral construct into a cell line for the first time, a range of volume, or Multiplicity of Infection (MOI), should be tested. 2, 5, 10, and 15 μL of lentiviral particles per 1.6 x 10^4 cells or MOIs of 0.5, 1, 2, and 5 should be used to determine the optimal transduction efficiency and knockdown for each cell line. Transduction efficiency can be optimized using the TurboGFP™ Control Transduction Particles (SHC003V).
Multiplicity of Infection (MOI):

Multiplicity of Infection (MOI) is the number of transducing lentiviral particles per cell. It is highly recommended that for each new cell type to be transduced, a range of MOI be tested.

To calculate:

\[
\text{(Total number of cells per well) \times (Desired MOI) = Total transducing units needed (TU)}
\]

\[
\text{(Total TU needed) / (TU/ml reported on C of A) = Total mL of lentiviral particles to add to each well}
\]

Day 3.

Remove the medium containing lentiviral particles from wells. Add fresh medium to a volume of 120 μL to each well.

**Note:** For cell types that do not strongly adhere to the plate, 100 μL of medium may be removed and replaced with 100 μL fresh medium.

Day 4.

Remove medium from wells. Add fresh medium containing puromycin.

**Note:** The appropriate concentration of puromycin for each cell type will vary. If the appropriate concentration for the desired cell type is unknown, a titration experiment, or kill curve, must be performed. Typically, 2–10 μg/ml are sufficient to kill most untransduced mammalian cell types.

Puromycin Titration:

Puromycin titration (kill curve) should be performed when working with a new cell type.

1. Plate 1.6 x 10^4 cells into wells of a 96-well plate with 120 μL fresh medium.
2. The next day add 500–10,000 ng/mL of puromycin to selected wells.
3. Examine viability every 2 days.
4. Culture for 3–14 days depending on the growth rate of the cell type and the length of time that cells would typically be under selection during a normal experimental protocol. Replace the medium containing puromycin every 3 days. The minimum concentration of puromycin that causes complete cell death after the desired time should be used for that cell type and experiment.

**Note:** Excess puromycin can cause many undesired phenotypic responses in most cell types.

Day 5 and on

a. Replace medium with fresh puromycin containing medium every 3–4 days until resistant colonies can be identified.

b. Pick a minimum of 5 puromycin-resistant colonies and expand each clone to assay for knockdown of the target gene.

c. A variety of phenotypic, enzymatic, or gene expression assays may be performed. Each assay should be optimized prior to the high-content screen with both negative and positive controls.

**Note:** Due to the random integration of the lentivirus into the host genome, varying levels of target gene knockdown may be seen with different puromycin resistant colonies. Testing a number of colonies will allow the optimal degree of knockdown to be determined.

**References**


<table>
<thead>
<tr>
<th>Catalog Number</th>
<th>Gene Family Set</th>
<th>Gene Count*</th>
<th>Clone Count*</th>
<th>Average Number Clones/Gene*</th>
</tr>
</thead>
<tbody>
<tr>
<td>SH1931</td>
<td>Apoptosis Pathway</td>
<td>443</td>
<td>3512</td>
<td>7.9</td>
</tr>
<tr>
<td>SH2931</td>
<td>B-Cell Activation</td>
<td>99</td>
<td>661</td>
<td>6.7</td>
</tr>
<tr>
<td>SH2231</td>
<td>Cell Adhesion Genes</td>
<td>368</td>
<td>2396</td>
<td>6.5</td>
</tr>
<tr>
<td>SH0831</td>
<td>Cytokine and Chemokine</td>
<td>106</td>
<td>538</td>
<td>5.1</td>
</tr>
<tr>
<td>SH1331</td>
<td>Cytokine and Chemokine Receptors</td>
<td>93</td>
<td>584</td>
<td>6.3</td>
</tr>
<tr>
<td>SH2331</td>
<td>Cytoskeleton Genes</td>
<td>275</td>
<td>1991</td>
<td>7.2</td>
</tr>
<tr>
<td>SH3031</td>
<td>Epigenetic Regulators</td>
<td>10</td>
<td>59</td>
<td>5.9</td>
</tr>
<tr>
<td>SH1831</td>
<td>DNA Repair Pathway</td>
<td>117</td>
<td>837</td>
<td>7.2</td>
</tr>
<tr>
<td>SH0731</td>
<td>Ubiquitin Hydrolases (DUBS)</td>
<td>127</td>
<td>830</td>
<td>6.5</td>
</tr>
<tr>
<td>SH2531</td>
<td>Extracellular Matrix Genes</td>
<td>331</td>
<td>1968</td>
<td>5.9</td>
</tr>
<tr>
<td>SH0231</td>
<td>G-Protein Coupled Receptors (GPCRs)</td>
<td>541</td>
<td>2864</td>
<td>5.3</td>
</tr>
<tr>
<td>SH2631</td>
<td>Helicase</td>
<td>136</td>
<td>909</td>
<td>6.7</td>
</tr>
<tr>
<td>SH1031</td>
<td>Ion Channel</td>
<td>277</td>
<td>1479</td>
<td>5.3</td>
</tr>
<tr>
<td>SH2731</td>
<td>JAK-STAT Pathway</td>
<td>190</td>
<td>1358</td>
<td>7.1</td>
</tr>
<tr>
<td>SH0131</td>
<td>Kinases, complete</td>
<td>678</td>
<td>7607</td>
<td>11.2</td>
</tr>
<tr>
<td>SH1131</td>
<td>Nuclear Hormone Receptors</td>
<td>218</td>
<td>1448</td>
<td>6.6</td>
</tr>
<tr>
<td>SH2431</td>
<td>p53 Pathway</td>
<td>242</td>
<td>1865</td>
<td>7.7</td>
</tr>
<tr>
<td>SH0431</td>
<td>Phosphatases</td>
<td>320</td>
<td>2099</td>
<td>6.6</td>
</tr>
<tr>
<td>SH2831</td>
<td>T-Cell Activation</td>
<td>242</td>
<td>1469</td>
<td>6.1</td>
</tr>
<tr>
<td>SH0531</td>
<td>Tumor Supressors</td>
<td>73</td>
<td>575</td>
<td>7.9</td>
</tr>
<tr>
<td>SH2131</td>
<td>Ubiquitin Ligases (E1, E2, E3)</td>
<td>349</td>
<td>2151</td>
<td>6.2</td>
</tr>
</tbody>
</table>

*The MISSION Production and Bio-informatics Team constantly reviews and confirms the clones available for each gene family set. These numbers are very close to the actual number that will be shipped, but each researcher will receive a final plate map indicating the exact TRCN clone numbers and their plate location.*
Troubleshooting Guide

<table>
<thead>
<tr>
<th>Problem</th>
<th>Cause</th>
<th>Solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low levels of target gene knockdown due to low transduction efficiency.</td>
<td>Hexadimethrine bromide not included during transduction.</td>
<td>Transduce in the presence of hexadimethrine bromide.</td>
</tr>
<tr>
<td></td>
<td>Non-dividing cell type used.</td>
<td>Transduce at a higher MOI.</td>
</tr>
<tr>
<td></td>
<td>MOI is too low.</td>
<td>Transduce at a higher MOI.</td>
</tr>
<tr>
<td></td>
<td>Cells were harvested and assayed too soon after transduction.</td>
<td>The shRNA must be permitted to accumulate in cells. Harvest 48–72 hours after transduction. Alternatively, knockdown results may be improved by placing cells under puromycin selection because untransduced cells will be killed.</td>
</tr>
<tr>
<td>No gene knockdown is observed.</td>
<td>Viral stock stored incorrectly.</td>
<td>Store stocks at –70 °C. Do not freeze/thaw more than 3 times.</td>
</tr>
<tr>
<td></td>
<td>MOI is too low.</td>
<td>Transduce at a higher MOI.</td>
</tr>
<tr>
<td>Cytotoxic effects observed after transduction.</td>
<td>Target gene is essential for cell viability.</td>
<td>Be sure that target gene is not essential for cell growth or viability.</td>
</tr>
<tr>
<td></td>
<td>Hexadimethrine bromide was used during transduction.</td>
<td>Be sure that cells are not sensitive to hexadimethrine bromide. Omit the hexadimethrine bromide during the transduction.</td>
</tr>
<tr>
<td></td>
<td>Too much puromycin was used for selection.</td>
<td>Determine the puromycin sensitivity of the cells by performing a kill curve and use the minimum concentration required to kill the untransduced cells.</td>
</tr>
</tbody>
</table>

Control Selection Table

The recommended controls for any shRNA experiment are described in the Control Selection Table and are closely aligned with the controls suggested in the Nature Cell Biology editorial.

<table>
<thead>
<tr>
<th>Recommended Control</th>
<th>Objective</th>
<th>Objective</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative Control: Untreated Cells</td>
<td>Untreated cells will provide a reference point for comparing all other samples.</td>
<td>MISSION pLKO.1-puro Control Transduction Particles, Catalog No. SHC001V The empty viral particles, produced from pLKO.1-puro, are a useful negative control that will not activate the RNAi pathway because they do not contain an shRNA insert. It will allow for observation of cellular effects of the transduction process. Cells transduced with the empty viral particles provide a useful reference point for comparing specific knockdown.</td>
</tr>
<tr>
<td>Negative Control: Transduction with empty viral particles, containing no shRNA insert</td>
<td>MISSION Non-Target shRNA Control Transduction Particles, Catalog No. SHC002V This non-targeting shRNA is a useful negative control that will activate RISC and the RNAi pathway, but does not target any human or mouse genes. The short-hairpin sequence contains 5 base pair mismatches to any known human or mouse gene. This allows for examination of the effects of shRNA transduction on gene expression. Cells infected with the non-target shRNA will also provide a useful reference for interpretation of knockdown.</td>
<td>MISSION TurboGFP Control Transduction Particles, Catalog No. SHC003V This is a useful positive control for measuring transduction efficiency and optimizing shRNA delivery. The TurboGFP Control transduction particles are produced from the lentiviral backbone vector, pLKO.1-puro, containing a gene encoding TurboGFP, driven by the CMV promoter. Transfection of this control provides fast visual confirmation of successful transduction.</td>
</tr>
<tr>
<td>Positive Control: Transduction with positive reporter viral particles</td>
<td>MISSION TurboGFP shRNA Control Transduction Particles, Catalog Number SHC004V The TurboGFP shRNA transduction particles are produced from the sequence-verified lentiviral plasmid, pLKO.1–Puro vector containing shRNA that targets TurboGFP (Catalog # SHC004). These particles can be used as a positive control to quickly visualize knockdown. This TurboGFP shRNA has been experimentally shown to reduce GFP expression by 99.6% in HEK 293T cells after 24 hours. Because this shRNA targets TurboGFP, and it does not target any human or mouse genes, it can also be used as a negative non-target control in shRNA experiments</td>
<td>IMISSION TurboGFP shRNA Control Transduction Particles, Catalog Number SHC004V The TurboGFP shRNA transduction particles are produced from the sequence-verified lentiviral plasmid, pLKO.1–Puro vector containing shRNA that targets TurboGFP (Catalog # SHC004). These particles can be used as a positive control to quickly visualize knockdown. This TurboGFP shRNA has been experimentally shown to reduce GFP expression by 99.6% in HEK 293T cells after 24 hours. Because this shRNA targets TurboGFP, and it does not target any human or mouse genes, it can also be used as a negative non-target control in shRNA experiments</td>
</tr>
</tbody>
</table>
Cell Type Table
The cell types listed below have been successfully infected by pLKO.1-puro based shRNA constructs

<table>
<thead>
<tr>
<th>Cell lines, human</th>
<th>Cell Type</th>
<th>Cell lines, human</th>
<th>Cell Type</th>
<th>Primary cells human</th>
<th>Cell Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEK293</td>
<td>embryonic kidney cells</td>
<td>A431</td>
<td>epidermal carcinoma</td>
<td>dendritic</td>
<td>immature dendritic</td>
</tr>
<tr>
<td>HeLa</td>
<td>cervical adenocarcinoma</td>
<td>THP1</td>
<td>monocytic</td>
<td>T-cells</td>
<td>lymphocytes</td>
</tr>
<tr>
<td>A549</td>
<td>lung adenocarcinoma</td>
<td>RAW264.7</td>
<td>macrophage</td>
<td>epithelial</td>
<td>prostate</td>
</tr>
<tr>
<td>H1299</td>
<td>lung carcinoma</td>
<td>SH-SY5Y</td>
<td>brain neuroblastoma</td>
<td>fibroblasts</td>
<td>primary mammary</td>
</tr>
<tr>
<td>HT29-D4</td>
<td>colon carcinoma</td>
<td>HCN-1A</td>
<td>brain cortical neuron</td>
<td>Primary cells, other species</td>
<td>Cell Type</td>
</tr>
<tr>
<td>HepG2</td>
<td>hepatocellular carcinoma</td>
<td>SupT1</td>
<td>T-cells</td>
<td>ECS</td>
<td>mouse embryonic stem cells</td>
</tr>
<tr>
<td>HCT116</td>
<td>colon carcinoma</td>
<td>BJ-TERT</td>
<td>diploid fibroblasts</td>
<td>fibroblasts</td>
<td>mouse embryonic fibroblasts</td>
</tr>
<tr>
<td>MCF7</td>
<td>breast carcinoma</td>
<td>Cell lines, mouse</td>
<td>Cell Type</td>
<td>MC3T3-E1</td>
<td>mouse bone marrow derived</td>
</tr>
<tr>
<td>MCF10A</td>
<td>breast carcinoma</td>
<td>NIH3T3</td>
<td>fibroblast</td>
<td>molar mesenchymal</td>
<td>mouse embryonic mesenchymal</td>
</tr>
<tr>
<td>Panc-1</td>
<td>pancreatic epithelioid carcinoma</td>
<td>Primary cells, human</td>
<td>Cell Type</td>
<td>cardiomyocytes</td>
<td>rat neonatal cardiomyocytes</td>
</tr>
<tr>
<td>PC3</td>
<td>prostate carcinoma</td>
<td>astrocytes</td>
<td>normal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DU145</td>
<td>prostate carcinoma</td>
<td>C3H10T1/2</td>
<td>mesenchymal</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Reviews Indicating the Importance of Each of the Gene Family Sets-

Apoptosis Pathway

B Cell Activation

Cell Adhesion

Cytokine and Chemokine Receptors

Cytokines and Chemokines

Cytoskeleton
DNA Repair Pathway

DUBS - Ubiquitin Hydrolases

Epigenetic Regulators

Extracellular Matrix

G-Protien-Coupled Receptors:

Helicases

Ion Channels

JAK-STAT Pathway

Kinases

Nuclear Hormone Receptors

p53 Pathway

Phosphatases

T Cell Activation

Tumor Suppressors
Ubiquitin Ligases (E1, E2, E3)


Limited Use Licenses:

Use of this product for Commercial Purposes requires a license from Sigma-Aldrich Corporation. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party, or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. Commercial Purposes means any activity by a party for consideration, but excludes not-for-profit core facilities providing services within their own research institutions at cost. Core facilities are invited to join Sigma-Aldrich’s RNAi Partnership Program. Details of Sigma-Aldrich’s RNAi Partnership Program can be found at www.sigma.com/rpp.

The MISSION shRNA Library of The RNAi Consortium is produced and distributed under license from the Massachusetts Institute of Technology.

Licensed under Carnegie Institution US Patent 6,506,559 and Massachusetts Institute of Technology and for laboratory and commercial research use only.

This product is licensed under U.S. Pat. Nos. 5,817,491; 5,591,624; 5,716,832; 6,312,682; 6,669,936; 6,235,522; 6,924,123 and foreign equivalents from Oxford BioMedica (UK) Ltd., Oxford, UK, and is provided for use in academic and commercial *in vitro* and *in vivo* research for elucidating gene function, and for validating potential gene products and pathways for drug discovery and development, but excludes any use of LentiVector® technology for: creating transgenic birds for the purpose of producing useful or valuable proteins in the eggs of such transgenic birds, the delivery of gene therapies, and for commercial production of therapeutic, diagnostic or other commercial products not intended for research use where such products do not consist of or incorporate a lentiviral vector.

Information about licenses for commercial uses excluded under this license is available from Oxford BioMedica (UK), Ltd., Medawar Center, Oxford Science Park, Oxford OX4 4GA UK enquiries@oxfordbiomedica.co.uk or BioMedica Inc., 11622 El Camino Real #100, San Diego CA 92130-2049 USA. LentiVector is a registered US and European Community trademark of Oxford BioMedica plc.

This product is licensed under agreement with Benitec Australia Ltd. and CSIRO as co-owners of U.S. Pat. No. 6,573,099 and foreign counterparts, for use in research to understand, diagnose, monitor, treat and prevent human diseases and disorders, including the use of animals for such research use, except that use of ddRNAi as a therapeutic agent or as a method of disease treatment, prevention, diagnosis or for disease monitoring is excluded. Information about licenses to these patents for use of ddRNAi as a therapeutic agent or for other uses excluded under this license is available from Benitec at licensing@benitec.com. Information about licenses for the use of ddRNAi in other fields, is available from CSIRO at pi.csiro.au/RNAi.

This product (based upon the lentikat system) is sublicensed from Invitrogen Corporation under U.S. Patent Nos. 5,686,279, 5,834,256, 5,858,740; 5,994,136; 6,135,516; 6,051,427, 6,165,782, and 6,218,187 and corresponding patents and applications in other countries for internal research purposes only. Use of this technology for gene therapy applications or bioprocessing other than for nonhuman research use requires a license from Cell Genesys, Inc. Please contact Cell Genesys, Inc. at 342 Lakeside Drive, Foster City, California 94404. Use of this technology to make or sell products or offer services for consideration in the research market requires a license from Invitrogen Corporation, 1600 Faraday Ave., Carlsbad, CA 92008.

This product is for non-clinical research use only. It is not to be used for commercial purposes. Use of this product to produce products for sale or for diagnostic, therapeutic or high throughput drug discovery purposes (the screening of more than 10,000 compounds per day) is prohibited. This product is sold under license from Invitrogen Corporation. In order to obtain a license to use this product for these commercial purposes, contact The Regents of the University of California. This product or the use of this product is covered by U.S. Patent No. 5,624,803 owned by The Regents of the University of California.

This Product is covered by US and foreign patent applications or patents and other proprietary intellectual property rights owned by CSHL ("CSHL shRNA IP Rights"), including U.S. Patent Nos. 8,153,776, 8,202,846, 8,383,599, 8,829,264, and EP1546174.
Subject to acceptance and all terms and conditions of this License, sale of the Product to Buyer by Sigma-Aldrich, Co. (acting under its license, an "Authorized Sale") conveys to Buyer only the nonexclusive, nontransferable right (with no right to sublicense) under the shRNA IP Rights to use the Product solely for Customer's internal research purposes, and only at its facility where the Product is delivered by Sigma-Aldrich, Co.

The Product is for research use only and may not be used in vitro or in vivo for any diagnostic, preventative, therapeutic or vaccine application, or used (directly or indirectly) in humans for any purpose.

Non-Profit Buyers. If Buyer is a Non-Profit Entity, then the following additional restrictions will apply:

Customer obtains no right to use, develop or otherwise exploit the product for any commercial purpose.

Commercial Buyers. If Buyer is a Commercial Entity, then the following additional restrictions will apply:

A Product sale is an Authorized Sale only if Buyer has already entered into a separate written agreement that has been executed by CSHL or Hairpin Technologies, that covers the CSHL shRNA IP Rights, and that is then currently in effect. Any delivery or transfer of Product to Customer outside of an Authorized Sale is void, conveys no implied or express right under this license and Customer will immediately return Product to Sigma-Aldrich for a refund.

"Commercial Entity" means any entity or organization other than a Non-Profit Entity.

"CSHL" means Cold Spring Harbor Laboratory.


"Non-Profit Entity" means any college, university or governmental entity (including without limitation, governmental and quasi-governmental institutes and research laboratories), or any non-profit scientific, research or educational organization of the type described in section 501(c)(3) of the Internal Revenue Code or qualified under a state non-profit organization statute.

"Product" means a product (including, without limitation, expression vectors encoding a shRNA, the design, manufacture or use of which (in whole or in part) is the subject of the shRNA IP Rights, and is deemed to include all components, progeny, reproductions, modified versions and other derivatives thereof.

This license is subject to a license from CSHL or Hairpin Technologies, and CSHL and Hairpin Technologies reserves all other rights under its license. For information on licensing rights for Commercial Entities, including use of this product for purposes other than research and trial licenses, please contact Hairpin Technologies, Inc. at info@hairpintechnologies.com or call (631) 881-0844.

MISSION is a registered trademark of Sigma-Aldrich Co. LLC.
TurboGFP is a trademark of Evrogen Co.